IIROC Trade Resumption - AVBT

Trading resumes in:

Company: Avisa Diagnostics Inc. (formerly FogChain Corp.)

CSE Symbol: AVBT (formerly FOG.X)

Resumption (ET): 9:30 AM 5/18/2021

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada .

SOURCE Investment Industry Regulatory Organization of Canada (IIROC)

Cision View original content: https://www.newswire.ca/en/releases/archive/May2021/17/c1923.html

News Provided by Canada Newswire via QuoteMedia

pharmaceutical investingcse:fog.x
The Conversation (0)

FogChain

FogChain Corp operates as a software as a service company. It provides a next-generation platform that seamlessly integrates application development and deployment that leverages a high-performance Fog based computing network to drive scale, and connects with the unique and ground-up built RadJav Blockchain. It operates in two segments namely Project development and Support and maintenance.

FogChain Corp operates as a software as a service company. It provides a next-generation platform that seamlessly integrates application development and deployment that leverages a high-performance Fog based computing network to drive scale, and connects with the unique and ground-up built RadJav Blockchain. It operates in two segments namely Project development and Support and maintenance. Keep Reading...
InMed Announces Results of 2025 Annual General and Special Meeting

InMed Announces Results of 2025 Annual General and Special Meeting

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders... Keep Reading...
InMed Provides Update on BayMedica Commercial Business

InMed Provides Update on BayMedica Commercial Business

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement.Recently, H.R. 5371, the "Continuing... Keep Reading...
Thian Chew, CEO of Invion

Invion Advances Global Strategy With New Licencing Agreement

Invion (ASX:IVX) has taken a major step forward with a new global licencing agreement that streamlines its rights across key cancer and infectious disease programs. The move gives the company a clearer path to advance its Photosoft technology, expand market opportunities and strengthen... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market is set to surpass a total value of US$1.75 trillion by the end of the decade, according to Evaluate Pharma.Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma... Keep Reading...
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Data demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company... Keep Reading...
InMed Pharmaceuticals (NASDAQ:INM)

InMed Pharmaceuticals

Keep Reading...

Latest News

Interactive Chart

Latest Press Releases

CORRECTION: Nextech3D.ai Provides Shareholder Update on Krafty Labs Acquisition and Announces $321,917 CEO Investment

Canadian Investment Regulatory Organization Trade Resumption - SICO

Steadright Grants Stock Options

Silverco Confirms No Material Change

Related News

Silver Investing

Craig Hemke: Silver, Gold's "Outstanding" Year — Will 2026 Bring a Repeat?

Oil and Gas Investing

5 Best-performing Canadian Oil and Gas Stocks of 2025

Lithium Investing

Altius Minerals to Expand Portfolio with C$520 Million Lithium Royalty Deal

Resource Investing

What is the Santa Claus Rally and Has it Arrived?

Gold Investing

What Was the Highest Price for Gold?

silver investing

What Was the Highest Price for Silver?

Precious Metals Investing

Canadian Investment Regulatory Organization Trade Resumption - SICO